QualityDipStocks / Health Care · Medical instruments
Stevanato Group S.p.A. STVN
Outside our quality screen, so we don’t track its dips. It’s 22% below its 52-week high.
Outside our quality screen. No fair value estimate for now: the model’s result is too extreme to stand behind.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −22%
- Risk vs market
- Market-likebeta 1.07
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for STVN: the model gives 91% below the price; trailing free cash flow is small next to the company's value, so a DCF on it says little. We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, STVN’s free cash flow would need to grow about 54% a year for five years; our estimate uses 6%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much STVN moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 3.6× the S&P 500’s.
- Beta vs S&P 500
- 1.07
- Volatility
- 46% vs 13% SPY
- Correlation SPY
- 0.30
- Correlation QQQ
- 0.22
How it ranks
Where STVN stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Free cash flow yield0.5% · free cash flow vs market capLowest 18%of 1,391
- Dividends + buybacks yield0.3% · cash paid out or used to retire shares, vs market capLowest 23%of 1,836
- Revenue growth, last 12 months+7.4% · vs the 12 months beforeLowest 40%of 1,814
- Operating margin17% · of sales kept as operating profitTop 36%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
Balance sheetOperating income covers interest 35× over.
ProfitabilityOperating margin of 17%, above the 9.3% median for the 175 Health Care companies we cover.
GrowthDiluted EPS grew 19% in the last fiscal year, above the 8.2% median for the 103 Health Care companies we cover.
ValuationPrice / book of 3.2×, below the 5.2× median for the 217 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree-cash-flow yield is just 0.5% (price / FCF 216×), so the price leans on future growth.
ProfitabilityGross margin of 29%, below the 62% median for the 146 Health Care companies we cover.
Cash returnsDividend yield of 0.3%, below the 1.0% median for the 58 Health Care companies we cover.
GrowthSales grew 6.4% a year over the last three fiscal years, below the 11% median for the 199 Health Care companies we cover.
RiskReports earnings Nov 3 (consensus EPS $0.17): results can move the price sharply and reset Market Value.
All fundamentals
P/E 34.4 · FCF yield 0.5% · ROE 10%
Valuation
- P/E
- 34.4×Health Care median 29.0×
- Price / FCF
- 215.6×
- FCF yield
- 0.5%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 4.06×
- Price / book
- 3.24×
- Market cap
- $5.4Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $1.3B
- Sales growth, 12 months
- +7.4%vs the 12 months before
- Sales growth, 3 yrs
- +6.4%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.51
- EPS growth, last FY
- +18.6%
- Net income, 12 months
- $157M
- Net income growth
- +19%12 months vs before
Profitability
- Gross margin
- 29.0%
- Operating margin
- 16.8%
- Net margin
- 11.8%
- FCF margin
- 1.9%
- Return on equity
- 10%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $146M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 35.4×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $25M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0.31%$17M paid
- Payout ratio
- 11%
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Stevanato Group S.p.A.’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +8%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield0.5%
- Free-cash-flow margin−8%
- Gross margin29%
- Operating margin17%
- Return on invested capital24%
- Return on equity9%
- Sales growth (latest quarter vs year-ago quarter)+8%
- Net debt / EBITDA1.2×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $19.74
- 52-wk lowlowest close, 1 year$13.43−32.0%
- PriceMon Nov 2 close$19.74you are here
- 52-wk highhighest close, 1 year$25.22+27.8%
Momentum & 52-week range
RSI 49 · 5 days −0.7%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$0.17
- Year-ago EPS$0.16
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
STVN is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Stevanato Group S.p.A. in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.